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Interleukin-20 plays a critical role in maintenance 
and development of psoriasis in the human 
xenograft transplantation model
Interleukin (IL)-20 is a recently discovered cytokine displaying increased 
levels in psoriatic lesions. Interestingly, IL-20 levels decrease with anti-
psoriatic treatment, correlating with clinical improvement. However, the 
role of IL-20 in the aetiology of psoriasis is unknown. The effects both of 
blocking IL-20 signalling in psoriatic plaques and of adding IL-20 to non-
lesional psoriasis skin were studied. The human skin xenograft transplanta-
tion model was employed in which psoriatic plaques and nonlesional ker-
atome skin biopsies obtained from donors with moderate to severe plaque 
psoriasis were transplanted on to immune deficient mice. The transplanted 
mice were treated with anti-IL-20 antibodies or recombinant human IL-20. 
Blocking IL-20 signalling with anti-IL-20 antibodies induced psoriasis reso-
lution and inhibited psoriasis induction. Continuous IL-20 infusion, togeth-
er with injection of additional nonactivated leucocytes, promoted induc-
tion of psoriasis in nonlesional skin from patients with psoriasis. The results 
suggest that IL-20 plays a critical role in the induction and maintenance of 
psoriasis, and IL-20 is suggested as a new possible specific target in psoria-
sis treatment. Br J Dermatol 2009; 160: 284–96.
Hand eczema classification:  
a cross-sectional, multicentre study of aetiology  
and morphology of hand eczema
Hand eczema is a long-lasting disease with a high prevalence in the back-
ground population. The disease has severe, negative effects on quality of 
life and sometimes on social status. Epidemiological studies have iden-
tified risk factors for onset and prognosis, but treatment of the disease is 
rarely evidence based, and a classification system for different subdiag-
noses of hand eczema is not agreed upon. Randomized controlled trials 
investigating treatment of hand eczema are called for. For this, as well as 
for clinical purposes, a generally accepted classification system for hand 
eczema is needed. Diepgen et al. attempted to characterize subdiagnoses 
of hand eczema with respect to basic demographics, medical history and 
morphology. A classification system is proposed on the basis of clinical 
data from 416 patients with hand eczema from 10 European patch test 
clinics. It is suggested that this classification be used in clinical work and in 
clinical trials. Br J Dermatol 2009; 160: 353–8.
Pulsed dye laser vs. intense pulsed light for port-
wine stains: a randomized side-by-side trial with 
blinded response evaluation
The pulsed dye laser (PDL) is considered the treatment of choice for port-
wine stains (PWS). Studies have suggested broadband intense pulsed light 
(IPL) to be efficient as well. So far, no studies have directly compared the 
PDL with IPL in a randomized clinical trial. Twenty patients with PWS (face, 
trunk, extremities; pink, red and purple colours; skin types I–III) received 
one side-by-side treatment with PDL (V-beam Perfecta, 595 nm, 0.45–1.5 
ms; Candela Laser Corporation, Wayland, MA, U.S.A.) and IPL (StarLux, 
Lux G prototype handpiece, 500–670 and 870–1400 nm, 5–10 ms; 
Palomar Inc., Burlington, MA, U.S.A.). Settings depended on the preopera-
tive lesional colour. Treatment outcome was evaluated by blinded, clinical 
evaluations and by skin reflectance measurements. Both PDL and IPL light-
ened PWS. Median clinical improvements were significantly better for PDL 
(65%) than IPL (30%) (P = 0.0004). A higher proportion of patients obtained 
good or excellent clearance rates with the PDL (75%) compared with IPL 
(30%) (P = 0.0104). Skin reflectance also documented better results after 
PDL (33% lightening) than IPL (12% lightening) (P = 0.002). Eighteen of 20 
patients preferred to receive continued treatments with PDL (P = 0.0004). 
No adverse events were observed with PDL or IPL. Both the specific PDL 
and IPL types of equipment used in this study lightened PWS and both were 
safe with no adverse events. Overall, the PDL with the specific treatment 
variables used in this study conveyed the advantages of better efficacy and 
higher patient preference. Br J Dermatol 2009; 160: 359–64.
Prospective study of surgery to the skin  
in smokers vs. nonsmokers
The association between smoking and complications following skin sur-
gery was studied. In a 5-year prospective observational study 7224 lesions 
were excised in 4197 patients. Patients were not instructed regarding smok-
ing. In total, 439 smokers (10.5%) underwent 646 procedures (9%) and 
3758 nonsmokers (89.5%) underwent 6578 procedures (91%). Smokers 
were younger (55 ± 16 years) than nonsmokers (66 ± 17 years) (P < 0.001). 
Infection incidence was not significantly different, 1.9% (12/646) in smok-
ers compared with 2.2% (146/6578) in nonsmokers (P = 0.55). There were 
two bleeds in smokers (0.3%) vs. 50 in nonsmokers (0.8%) (P = 0.2). The 
incidence of wound dehiscence in nonsmokers (n = 3) was not different 
from that in nonsmokers (n = 21) (P = 0.54). However, the incidence of 
scar contour distortion in smokers (n = 3) was greater than in nonsmok-
ers (n = 2) (odds ratio 15.3, 95% confidence interval 2.5–92). Total com-
plication incidence was similar: 3.6% in smokers vs. 4.0% in nonsmok-
ers (P = 0.58). Out of 2371 flaps there were 14 (0.6%) cases of end-flap 
necrosis but smokers were not at increased risk. The case–control analysis 
compared each smoker with two nonsmokers matched for age, sex, postal 
code and outdoor occupational exposure. This again demonstrated no dif-
ference in infection, scar complication, bleed, dehiscence, end-flap necro-
sis or total complication incidence. Smokers and nonsmokers show similar 
skin surgery complications. The increased risk of contour distortion identi-
fied was difficult to interpret. Advice to cease smoking in the short term to 
improve outcomes with skin cancer surgery is not supported by these data. 
Br J Dermatol 2009; 160: 365–7.
Economic evaluation of etanercept in the 
management of chronic plaque psoriasis
The National Institute for Health and Clinical Excellence has recommend-
ed that etanercept 25 mg twice weekly (biw) be used in adults with severe 
plaque psoriasis. However, its economic model did not consider the alter-
native licensed regimen of etanercept 50 mg biw. The cost-effectiveness was 
assessed of etanercept 50 mg biw for the treatment of chronic plaque pso-
riasis, and the characteristics explored of patients who benefited most from 
50 mg dosing. An economic model was constructed to estimate the incre-
mental cost per quality-adjusted life year (QALY) gained. The model consid-
ered patients with chronic plaque psoriasis who had both Psoriasis Area and 
Severity Index (PASI) and Dermatology Life Quality Index (DLQI) of 10 or 
higher who were unable to take standard systemic therapies. Quality of life 
gain was estimated from the DLQI responses of patients enrolled in three clin-
ical studies. The model considered expenditure on drugs, monitoring visits, 
adverse events and inpatient stays. Costs were estimated from the perspective 
of the U.K. National Health Service over a time period of 10 years. The incre-
mental cost per QALY for etanercept 50 mg biw compared with no systemic 
therapy was found to be £6217 (95% confidence interval £5396–7486). The 
cost-effectiveness of 50 mg dosing was more attractive in patients with base-
line PASI ≥ 20 (£5163) or baseline DLQI ≥ 20 (£4599). This model found the 
licensed dose regimen of etanercept 50 mg biw to be cost-effective in the 
U.K. This regimen was particularly appropriate for patients with severe dis-
ease or poor quality of life at baseline. Br J Dermatol 2009; 160: 380–6.
